专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2020242376A1 METHOD OF TREATING A SALL4-EXPRESSING CANCER 审中-公开
公开(公告)号：WO2020242376A1
公开(公告)日：2020-12-03
申请号：PCT/SG2020/050296
申请日：2020-05-19
申请人： AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH , NATIONAL UNIVERSITY OF SINGAPORE , BRIGHAM & WOMEN'S HOSPITAL
发明人： TAN, Lee Hong Justin , TAM, Wai Leong , S/O KANAGASUNDARAM, Yoganathan , NG, Siew Bee , TENEN, Daniel Geoffrey , CHAI, Li
IPC分类号： A61K31/365 , A61K31/5377 , A61K36/06 , A61P35/00 , G01N33/574
摘要： The present disclosure relates generally to the field of oncology. In particular, the invention discloses a method of treating a Sal-like protein 4 (SALL4) expressing cancer in a subject, the method comprising administering an inhibitor of mitochondrial oxidative phosphorylation (OXPHOS) for a sufficient time and under conditions to treat the subject of the SALL4 expressing cancer. Examples of the OXPHOS inhibitors include Oligomycin, Efrapeptin, Antimycin, Leucinostatin and PI-103.

2. 发明申请

WO2020101571A1 METHODS FOR MANIPULATING CELL STATE TRANSITIONS IN CANCER 审中-公开
公开(公告)号：WO2020101571A1
公开(公告)日：2020-05-22
申请号：PCT/SG2019/050549
申请日：2019-11-11
申请人： AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
发明人： TAM, Wai Leong , LOO, Ser Yue , TOH, Li Ping
IPC分类号： C12N5/09 , A61K31/00 , A61K45/06 , A61P35/00
摘要： The present invention relates to a method of inducing mesenchymal-epithelial transition (MET) in a basal-like (or mesenchymal-like) cancer cell by contacting the cancer cell with an inducer of mesenchymal-epithelial transition for a time and under conditions sufficient to induce MET in the cell. Additionally, there is also provided a method of inhibiting epithelial-mesenchymal transition (EMT) of a cancer in a subject, the method comprising administering an inhibitor or regulator of lipid metabolism for a sufficient time and under conditions to inhibit epithelial mesenchymal transition (EMT) of the cancer in the subject.

3. 发明申请

WO2017176215A1 CANCER BIOMARKERS AND METHODS OF USE 审中-公开
标题翻译：癌症生物标志物和使用方法
公开(公告)号：WO2017176215A1
公开(公告)日：2017-10-12
申请号：PCT/SG2017/050197
申请日：2017-04-06
申请人： AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
发明人： LIM, Bing , ZHANG, Wencai , TAM, Wai Leong
IPC分类号： A61K31/7088 , C12N15/113 , C12Q1/68 , A61P35/00
摘要： The present disclosure relates to a method of determining the presence of lung cancer in a subject comprising the steps of detecting an expression level of miR-1246 alone or in combination with an expression level of miR-1290 in a sample obtained from the subject wherein the increase in miR-1246 and/or miR-1290 in the sample obtained from the subject relative to the expression level of miR-1246 or miR-1290 in the control sample indicates the presence of lung cancer in the subject. The disclosure further comprises a method of monitoring a response to therapy in a lung cancer patient, a method of prognosis of lung cancer in a patient and a method for treating lung cancer in a subject comprising the use of inhibitors of miR-1246 and/or miR-1290 alone or in combination. In a specific embodiment, miR-1246 and/or miR-1290 levels are used to predict response to chemotherapy and progression in human non-small cell lung cancer (NSCLC) patients.
摘要翻译：本发明涉及确定受试者中肺癌存在的方法，其包括以下步骤：单独检测miR-1246的表达水平或与miR-1290的表达水平组合从受试者获得的样品，其中相对于对照样品中miR-1246或miR-1290的表达水平，从受试者获得的样品中miR-1246和/或miR-1290的增加表明存在主题。本公开进一步包括监测肺癌患者对治疗的反应的方法，患者中肺癌预后的方法以及治疗受试者中肺癌的方法，其包括使用miR-1246的抑制剂和/或 miR-1290单独或组合。在一个具体的实施方案中，使用miR-1246和/或miR-1290水平来预测人非小细胞肺癌（NSCLC）患者对化疗和进展的反应。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式